NCT04864821View on ClinicalTrials.gov

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

May 14, 2022

Study Completion Date

May 14, 2023

Conditions
OsteosarcomaNeuroblastomaGastric CancerLung Cancer
Interventions
DRUG

Targeting CD276 CAR T cells

Targeting CD276 autologous chimeric antigen receptor T cells

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY